MediWound (NASDAQ:MDWD) Stock Breaks Below 50-Day Moving Average – What’s Next?

Posted by George Bondi on Oct 7th, 2026

MediWound Ltd. (NASDAQ:MDWD – Get Free Report) crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $13.58 and traded as low as $13.30. MediWound shares last traded at $13.51, with a volume of 49,885 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Oppenheimer restated an “outperform” rating and issued a $30.00 price target (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. TD Cowen reissued a “buy” rating on shares of MediWound in a research note on Thursday, September 24th. Weiss Ratings cut shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Alliance Global Partners reaffirmed a “buy” rating on shares of MediWound in a report on Wednesday, September 16th. Finally, Wall Street Zen upgraded MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 26th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.00.

View Our Latest Research Report on MDWD

MediWound Stock Down 2.3%

The company’s 50 day moving average price is $13.55 and its two-hundred day moving average price is $14.88. The firm has a market cap of $165.15 million, a PE ratio of -7.14 and a beta of 0.09.

MediWound (NASDAQ:MDWD – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The firm had revenue of $3.09 million for the quarter, compared to the consensus estimate of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. On average, analysts expect that MediWound Ltd. will post -2.37 earnings per share for the current fiscal year.

Insider Buying and Selling at MediWound

In other news, COO Shmuel Hess sold 3,958 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total value of $51,137.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On MediWound

An institutional investor recently raised its position in MediWound stock. Silverberg Bernstein Capital Management LLC lifted its stake in MediWound Ltd. (NASDAQ:MDWD – Free Report) by 8.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 200,005 shares of the biopharmaceutical company’s stock after purchasing an additional 16,081 shares during the period. MediWound comprises about 1.8% of Silverberg Bernstein Capital Management LLC’s investment portfolio, making the stock its 16th largest position. Silverberg Bernstein Capital Management LLC owned 1.56% of MediWound worth $3,222,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

(Get Free Report)

MediWound Ltd. (NASDAQ: MDWD) is a biotechnology company focused on developing and commercializing innovative therapies for complex wounds. The company’s products are designed to remove damaged tissue, support wound healing and address unmet needs in burn care and chronic wounds.

MediWound’s lead commercial product is NexoBrid, a topical bromelain-based enzymatic treatment used to remove eschar—the dead tissue that can form after severe thermal burns. NexoBrid has received regulatory approvals in multiple markets, including the United States, the European Union and Israel, and is marketed for use in the treatment of deep partial-thickness and full-thickness burns.

The company is also developing EscharEx, an investigational topical treatment intended to enzymatically debride chronic wounds, including venous leg ulcers.